Rare Cancers

Pazopanib Shows Promise in von Hippel-Lindau Disease - A Rare Cancer Syndrome

Results from the first prospective trial of systemic treatment for von Hippel-Lindau (VHL) disease show that the antiangiogenic agent pazopanib (Votrient, Novartis) could offer a "realistic option" to surgical resection in patients with this rare, inherited cancer syndrome.

PARP Inhibitors Might Treat Two Rare Cancers

Researchers from Yale Cancer Center have found that PARP Inhibitors might offer an effective treatment paradigm for two rare inherited cancers, Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) and Succinate Dehydrogenase-related Hereditary Paraganglioma and Pheochromocytoma (SDH PGL/PCC).